Cited by 416Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Open access

Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., Kendall, D. M.·2006·Diabetes, Obesity and Metabolism

DOI 10.1111/j.1463-1326.2006.00602.x

Open this paper in CoChat — free account Open PDF

Abstract

Aim Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET). Methods This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total. Patients continued their SU and/or MET regimens throughout. Results Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 +/- 10 years, weight 99 +/- 21 kg, body mass index 34 +/- 6 kg/m2, A1C 8.3 +/- 1.0% (mean +/- SD)]. Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C Conclusion In summary, 82 weeks of adjunctive exenatide treatment in patients with DM2 treated with SU and/or MET resulted in sustained reduction in A1C and progressive reduction in weight, as well as improvement in some cardiovascular risk factors.

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2006.00602.x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citation
Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citation
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citation
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Diabetes trends in the U.S.: 1990-1998.
Mokdad, A. H., Ford, E. S., Bowman, B. A., Nelson, D. E., Engelgau, M. M., Vinicor, F., & Marks, J. S. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1278 · Cited by 1,042
World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects
(1997) · JAMA · doi:10.1001/jama.1997.03540350075038 · Cited by 1,023

Show all 31 references

Sorted by citations

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
WAJCHENBERG, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 722
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 702
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 605
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 534
Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528
GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515
The incretin system and its role in type 2 diabetes mellitus
Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447
Self-citation
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430
Self-citation
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes
Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 424
Self-citation
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
The Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults
Franz, M. J., Powers, M. A., Leontos, C., Holzmeister, L. A., Kulkarni, K. D., Monk, A. M., Wedel, N., & Gradwell, E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.014 · Cited by 324
Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D. M., & Sowers, J. R. (2012) · Obesity · doi:10.1002/oby.20181 · Cited by 296
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 265
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Ioannides‐Demos, L. L., Piccenna, L. G., & McNeil, J. J. (2010) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 241
Blood pressure‐lowering effects of GLP ‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
New Drugs for the Treatment of Diabetes
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 188
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 177
Self-citation
The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake
Grill, H. J., & Hayes, M. R. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.10 · Cited by 174
Intestinal Microbiota During Infancy and Its Implications for Obesity
Reinhardt, C., Reigstad, C. S., & Bäckhed, F. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318183187c · Cited by 180
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173
Manufacturing Peptides as Active Pharmaceutical Ingredients
Zompra, A. A., Galanis, A., Werbitzky, O., & Alberício, F. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.23 · Cited by 170
Metabolic Syndrome: From Global Epidemiology to Individualized Medicine
Batsis, J. A., Nieto-Martínez, R. E., & López-Jiménez, F. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100355 · Cited by 171
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 169
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 163
Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153
Self-citation
Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09077 · Cited by 152
Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Dushay, J. R., Gao, C., Gopalakrishnan, G. S., Crawley, M. B., Mitten, E. K., Wilker, E. H., Mullington, J. M., & Maratos–Flier, E. (2011) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 151
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 144
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P. G., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M. D., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 143
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Olmo-García, M. I. D., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 149
Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner
Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
Madsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 129
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
Liu, Q., Anderson, C. M., Broyde, A., Polizzi, C. J., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 125
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
Kovács, C. S., Seshiah, V., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H., & Broedl, U. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.511 · Cited by 113
Role of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
Bunck, M. C. M., Eliasson, B., Cornér, A., Heine, R. J., Shaginian, R. M., Taskinen, M., Yki‐Järvinen, H., Smith, U., & Diamant, M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01355.x · Cited by 112
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 112
Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats
Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011) · Obesity · doi:10.1038/oby.2011.50 · Cited by 110
Exenatide: a review from pharmacology to clinical practice
Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 108
Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting
Yoon, N. M., Cavaghan, M. K., Brunelle, R. L., & Roach, P. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.021 · Cited by 110
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., PETERSON, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 110
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 107
Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus solitarius is required for food intake control
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
Exenatide
Cvetkovi, R. S., & Plosker, G. L. (2007) · Drugs · doi:10.2165/00003495-200767060-00008 · Cited by 103
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
Niswender, K. D., Pi‐Sunyer, X., Buse, J. B., Jensen, K. H., Toft, A. D., Russell-Jones, D. L., & Zinman, B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01673.x · Cited by 98
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Incretin physiology beyond glucagon‐like peptide 1 and glucose‐dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides
Rehfeld, J. F. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02235.x · Cited by 99
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 99
Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents
Davis, S. N., Johns, D., Maggs, D. G., Xu, H., Northrup, J., & Brodows, R. G. (2007) · Diabetes Care · doi:10.2337/dc06-2532 · Cited by 95
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 94
Incretins and Amylin: Neuroendocrine Communication Between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose
Hayes, M. R., Mietlicki‐Baase, E. G., Kanoski, S. E., & Jonghe, B. C. D. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161201 · Cited by 94
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance
Taher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausová, Z., & Adeli, K. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.005 · Cited by 94
Exenatide efficacy and safety: a systematic review
Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02790.x · Cited by 90
The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1
Hayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. D. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 89
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., & Berneis, K. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241633 · Cited by 83
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Carolyn, F. D. (2007) · Frontiers in bioscience · doi:10.2741/2799 · Cited by 83
DPP‐IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
Kos, K., Baker, A. R., Jernås, M., Harte, A. L., Clapham, J. C., O’Hare, J. P., Carlsson, L. M. S., Kumar, S., & McTernan, P. G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00909.x · Cited by 83
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S. R. D., & Cherrington, A. D. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020007 · Cited by 82
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
Haering, H.-U., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Meinicke, T. W., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.044 · Cited by 79
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Hollander, P. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 81
Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
McKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79
Exenatide
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus
Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 79
Exploring the impact of bariatric surgery on high density lipoprotein
Aminian, A., Zelisko, A., Kirwan, J. P., Brethauer, S. A., & Schauer, P. R. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.07.017 · Cited by 80
Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner
Zhao, S., Kanoski, S. E., Yan, J., Grill, H. J., & Hayes, M. R. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.265 · Cited by 79
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 81
A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin
Liutkus, J., Guzmán, J. R., Norwood, P. C., Pop, L., Northrup, J., Cao, D., & TRAUTMANN, M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74
Self-citation
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
Blonde, L., Pencek, R., & MacConell, L. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0171-2 · Cited by 72
Self-citation
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 74
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
Irace, C., Luca, S. D., Shehaj, E., Carallo, C., Loprete, A., Scavelli, F. B., & Gnasso, A. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112449562 · Cited by 72
Incretin‐based treatment of type 2 diabetes: glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors*
Deacon, C. F. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00765.x · Cited by 69
The Effect of Sitagliptin Versus Glibenclamide on Arterial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients
Koren, S., Shemesh-Bar, L., Tirosh, A., Peleg, R. K., Berman, S., Hamad, R. A., Vinker, S., Golik, A., & Efrati, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0296 · Cited by 71
Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 68
Can Gut Hormones Control Appetite and Prevent Obesity?
Chaudhri, O. B., Wynne, K., & Bloom, S. R. (2008) · Diabetes Care · doi:10.2337/dc08-s269 · Cited by 71
Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
Boye, K. S., Matza, L. S., Oglesby, A. K., Malley, K. G., Kim, S. W., Hayes, R. P., & Brodows, R. G. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-80 · Cited by 68
Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
Liu, Q., Adams, L. A., Broyde, A., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
Gallwitz, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 63
Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
Klen, J., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073451 · Cited by 68

Authors: Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M.
Affiliations: Ochsner Medical Center (US)
Eli Lilly (Germany) (DE)
Corresponding author: Mac, S. M.
Kim, D. D.
ORCID: Blonde, L.
Han, J.
Kendall, D. M.
Venue: Diabetes, Obesity and Metabolism
Publisher: Wiley
Published: 2006-04-18
Volume: 8
Issue: 4
Pages: 436-447
ISSN: 1462-8902 (ISSN-L)
1463-1326
DOI: 10.1111/j.1463-1326.2006.00602.x
OpenAlex: W2093738306
Cited by: 416
References: 31
Citations by year: 2026: 1 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 3 · 2020: 5 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 15 · 2015: 15 · 2014: 19 · 2013: 24 · 2012: 45
FWCI: 38.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetes Obesity and Metabolism (publishedVersion)
PubMed (publishedVersion)
Funders: Amylin Pharmaceuticals
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: exenatide, type 2 diabetes, incretin mimetics, HbA1c, glycemic control, weight loss, cardiovascular risk factors, sulfonylureas, metformin, adjunctive therapy, long-term treatment, nausea, hypoglycemia
MeSH terms: Exenatide, Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Lipids, Male, Metformin, Middle Aged, Peptides, Risk Factors, Sulfonylurea Compounds, Venoms, Weight Loss, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks